Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma

Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma

Pleural mesothelioma (PM) is an aggressive cancer caused by asbestos exposure, with limited treatment options and poor prognosis, highlighting the need for more effective therapies. Combining immune checkpoint blockade with anti-angiogenic therapy has shown potential in other cancers. Our study inve...

Full description

Saved in:
Bibliographic Details
Main Authors: Sophie Rovers, Jonas Van Audenaerde, Ruben Verloy, Jorrit De Waele, Louize Brants, Christophe Hermans, Ho Wa Lau, Céline Merlin, Maria Möller Ribas, Peter Ponsaerts, Steven Van Laere, Filip Lardon, An Wouters, Scott A. Fisher, Jan van Meerbeeck, Elly Marcq, Evelien Smits
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
Anti-angiogenesis
cancer immunotherapy
combination therapy
immune checkpoint blockade
pleural mesothelioma
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2512104
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items